OBI Pharma, Inc.
Tuesday, June 04, 2024
Oncology
Company Presentation Theater 2
OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC platform technologies and has a novel oncology portfolio:
ADC platform technologies
- GlycOBI™
- ThiOBI™
Novel cancer therapeutics
- Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine)
- OBI-833 (Globo H cancer vaccine)
- OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)
- OBI-992 (TROP2 ADC, Cys-conjugation platform))
- OBI-902 (TROP2 ADC, GlycOBI platform)
- OBI-904 (Nectin4 ADC, GlycOBI platform)
Company Website:
https://www.obipharma.com/
Lead Product in Development:
Adagloxad simolenin
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Exchange
Taipei Exchange
Ticker
4174.TWO
Company HQ City
Taipei City
Company HQ State
Taipei
Company HQ Country
Taiwan
CEO/Top Company Official
Heidi Wang, PhD
Development Phase of Primary Product
Phase III
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())